


PRODUCT INFORMATION



Ponatinib (hydrochloride)

Item No. 35778

CAS Registry No.: 1114544-31-8
Formal Name: 3-(2-imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-N-[4-[(4-methyl-1-piperazinyl)methyl]-3-(trifluoromethyl)phenyl]-benzamide, monohydrochloride
Synonym: AP 24534
MF: $C_{29}H_{27}F_3N_6O \cdot HCl$
FW: 569.0
Purity: $\geq 98\%$
UV/Vis.: λ_{max} : 259, 267, 290, 301, 321 nm
Supplied as: A solid
Storage: $-20^{\circ}C$
Stability: ≥ 4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Ponatinib (hydrochloride) is supplied as a solid. A stock solution may be made by dissolving the ponatinib (hydrochloride) in the solvent of choice, which should be purged with an inert gas. Ponatinib (hydrochloride) is soluble in organic solvents such as DMSO and dimethyl formamide. The solubility of ponatinib (hydrochloride) in these solvents is approximately 11 mg/ml and 2 mg/ml respectively. Ponatinib (hydrochloride) is also slightly soluble in ethanol.

Description

Ponatinib is an orally bioavailable Bcr-Abl tyrosine kinase inhibitor ($IC_{50} = 0.37$ nM).¹ It inhibits the tyrosine kinase inhibitor-resistant mutant Bcr-Abl^{T315I} ($IC_{50} = 2$ nM), as well as Bcr-Abl^{Q252H}, Bcr-Abl^{Y253F}, Bcr-Abl^{M351T}, and Bcr-Abl^{H396P} mutants (IC_{50} s = 0.44, 0.3, 0.3, and 0.34 nM, respectively). It is selective for Bcr-Abl and these mutants over the insulin receptor, IGF-1R, Aurora A kinase, and Cdk2/cyclin E but does inhibit the receptor tyrosine kinases c-Src, VEGF receptor 2 (VEGFR2), FGFR1, and PDGFR α (IC_{50} s = 5.4, 1.5, 2.2, and 1.1 nM, respectively). Ponatinib inhibits proliferation of Ba/F3 cells expressing native ($IC_{50} = 0.5$ nM) or mutant Bcr-Abl (IC_{50} s = 0.5-36 nM) and induces apoptosis. It reduces tumor growth in a Ba/F3 Bcr-Abl^{T315I} mouse xenograft model when administered at doses ranging from 10 to 30 mg/kg. Formulations containing ponatinib have been used in the treatment of chronic-, accelerated-, or blast-phase chronic myeloid leukemia (CML), T315I-positive CML, or T315I-positive Philadelphia-chromosome positive acute lymphoblastic leukemia (Ph+ ALL).

Reference

1. O'Hare, T., Shakespeare, W.C., Zhu, X., *et al.* AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. *Cancer Cell* **16**(5), 401-412 (2009).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the [complete](#) Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 11/04/2022

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM